Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Allogene Therapeutics, Inc. Common Stock (ALLO)

Biological Products, (no Disgnostic Substances)

https://www.allogene.com

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/11/2018

Market Cap

478,866,480

Shares Outstanding

168,280,000

Weighted SO

168,276,662

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

GTHX --.--%

HRTX --.--%

ANNX --.--%

SGMO --.--%

BEAM --.--%

SANA --.--%

CRBU --.--%

EDIT --.--%

THRX --.--%

Beta

0.8500

Last Div

0.0000

Range

2.01-5.78

Chg

-0.0100

Avg Vol

2837233

Mkt Cap

478866480

Exch

NASDAQ

Country

US

Phone

650 457 2700

DCF Diff

2.3523

DCF

-0.0773

Div Yield

0.0000

P/S

5568.2149

EV Multiple

-1.5682

P/FV

0.8449

Div Yield %

0.0000

P/E

-1.5628

PEG

-0.1712

Payout

0.0000

Current Ratio

12.2537

Quick Ratio

12.2537

Cash Ratio

4.5749

DSO

8488.3721

DIO

0.0000

Op Cycle

8488.3721

DPO

72.1610

CCC

8416.2111

Gross Margin

-759.8372

Op Margin

-3148.6628

Pretax Margin

-3237.8023

Net Margin

-3237.8023

Eff Tax Rate

0.0099

ROA

-0.4305

ROE

-0.5376

ROCE

-0.4442

NI/EBT

1.0000

EBT/EBIT

1.0283

EBIT/Rev

-3148.6628

Debt Ratio

0.1456

D/E

0.1829

LT Debt/Cap

0.1445

Total Debt/Cap

0.1546

Int Coverage

-739.8497

CF/Debt

-2.4278

Equity Multi

1.2560

Rec Turnover

0.0430

Pay Turnover

5.0581

Inv Turnover

0.0000

FA Turnover

0.0006

Asset Turnover

0.0001

OCF/Share

-1.2036

FCF/Share

-1.2047

Cash/Share

2.3398

OCF/Sales

-2659.5814

FCF/OCF

1.0009

CF Coverage

-2.4278

ST Coverage

-31.6748

CapEx Coverage

-1137.9303

Div&CapEx Cov

-1137.9303

P/BV

0.8449

P/B

0.8449

P/S

5568.2149

P/E

-1.5628

P/FCF

-2.0918

P/OCF

-1.9026

P/CF

-1.9026

PEG

-0.1712

P/S

5568.2149

EV Multiple

-1.5682

P/FV

0.8449

DPS

0.0000

Latest Headlines (EST)

MarketWatch Jan 06, 05:58 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks Benzinga Jan 05, 14:32 Cell Therapy Focused Allogene Therapeutics' Resource Prioritization A Bold Move, Says Analyst Benzinga Jan 05, 14:32 Cell Therapy Focused Allogene Therapeutics' Resource Prioritization A Bold Move, Says Analyst GlobeNewswire Inc. Jan 04, 16:15 Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks GlobeNewswire Inc. Dec 09, 12:00 Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology GlobeNewswire Inc. Dec 09, 12:00 Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology GlobeNewswire Inc. Dec 09, 12:00 Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology GlobeNewswire Inc. Dec 09, 12:00 Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology GlobeNewswire Inc. Dec 09, 12:00 Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology GlobeNewswire Inc. Dec 01, 08:30 Allogene Therapeutics Announces Participation in December Investor Conference Zacks Investment Research Nov 24, 12:29 Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why GlobeNewswire Inc. Oct 30, 08:30 Allogene Therapeutics Announces Participation in November Investor Conferences

Revenue Product Segmentation